Objective:Insulin-like growth factor (IGF-I) action is influenced by circulating as well as tissue levels of its binding proteins. Because serum IGF binding protein-1 (IGFBP-1) levels have been found to be decreased in patients with polycystic ovary syndrome (PCOS), we tested the hypothesis that regulation of IGFBP-1 secretion may be different in patients with PCOS compared with normal women.
Methods:We studied 15 normal ovulatory women and 15 women with PCOS of similar age (21 ± 1 and 22 ± 1 years, respectively). All subjects were studied after an overnight fast between days 5-8 after spontaneous or progestin-induced menses. Perturbations included the administration of insulin intravenously, maintenance of a euglycemic clamp, and, in a subsequent cycle, the administration of a long-acting somatostatin analogue (octreotide, 100 μg) given subcutaneously. Blood samples were collected before treatment, every 15 minutes for 6 hours after insulin, and every 30 minutes for 3 hours after octreotide administration. Serum levels of IGF-I, IGFBP-1, IGFBP-3, and insulin were measured by specific immunoassays.
Results:Compared with the controls, patients with PCOS had significantly higher insulin levels, similar IGF-I and IGFBP-3 levels, and significantly lower IGFBP-1. INsulin did not change serum IGF-I levels in either group, although a significant decrease in IGFBP-1 levels occurred in normal women but ot in patients with PCOS. Octreotide treatment also did not change serum IGF-I levels in either group, but serum insulin levels decreased significantly and IGFBP-1 levels increased significantly in both groups; this response was significantly greater in controls.
Conclusion:Our data are compatible with the notion that regulation of IGFBP-1 is altered in women with PCOS and that several factors may be involved.
1. Poretsky L, Kalin MF. The gonadotropic function of insulin. Endocr Rev1987;8:132-141.
2.
2. Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril1988;50:197-212.
3.
3. Adashi EY, Resnick CE, Hernandez Er, Svoboda ME, Van Wyk JJ. The potential relevance of insulin-like growth factor-1 to ovarian physiology from basic science to clinical application. Semin Reprod Endocrinol1989;7:94-100.
4.
4. Giudice L. Insulin-like growth factors and ovarian follicular development. Endocr Rev1992;13:641-669.
5.
5. Lindheim SR, Kaoles WW, Wassily VM, et al. Effects of IGF-I and insulin in PCOS. Abstract no. S3, p. 70-70. Presented at the 40th Annual Meeting of the Society for Gynecologic Investigation, Tronto, Canada, 1993.
6.
6. Nagamani M, Dingh TV, Kelve ME. Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol1986;154:384-389.
7.
7. Sara VR, Hall K. Insulin-like growth factors and their binding-proteins. Physiol Rev1990;70:591-614.
8.
8. Shimasaki S, Ling N. Identification and molecular characteristics of insulin-like growth factor binding proteins (IGFBP-1,2,3,4,5, and 6). Prog Growth Factor Res1992;3:243-266.
9.
9. Angervo M, Koistinen R, SUikkari AM, Seppäla M. Insulin-like growth factor binding protein-1 inhibits the DNA amplification induced by insulin-like growth factor-1 in human granulosa luteal cells. Hum Reprod1991;6:770-773.
10.
10. Morris R, Carmina E, Vijod MA, Stranczyk FZ, Lobo RA. Alterations in the sensitivity of serum IGF-I and IGF-BP3 to octreotide in polycystic ovary syndrome. Fertil Steril1995;63:742-746.
11.
11. Suikkari AM, Ruutainen K, Eckolla R, Seppäla M. Low levels of low-molecular weight plasma insulin-like growth factor binding protein in women with polycystic ovarian disease. Hum Reprod1989;4:136-139.
12.
12. Homburg R, Pariente C, Lunenfeld B, Jacobs HS. The role of insulin-like growth-factor-1 (IGF-I) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome. Hum Reprod1992;7:1379-1383.
13.
13. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocrimol Rev1989;10:68-91.
14.
14. El-Roeiy A, Chen X, Robets VJ, LeRoith D, Roberts CT, Yen SSC. Expression of insulin-like growth factor I (IGF-I) and IGF-II and the IGF-I, IGF-II, and insulin receptor genes and localization of the gene products in the human ovary. J Clin Endocrinol Metab1993;77:1411-1418.
15.
15. Jesionowska H, Hemmings R, Guyda HJ, Posner BL. Determination of insulin and insulin-like growth factors in the ovarian circulation. Fertil Steril1990;53:88-91.
16.
16. Eden JA, Jones J, Carter GD, Alaghband-Zadeh J. A comparison of follicular fluid levels of insulin-like growth factor-I in normal dominant and cohort follicles, polycystic and multicystic ovaries. Clin ENdocrinol1988;29:327-336.
17.
17. Kazer RR, Unterman TG, Glick RP. An abnormality of the growth hormone/insulin like growth factor-I axis in women with polycystic ovary syndrome. J Clin Endocrinol Metab1990;71:958-962.
18.
18. Mason HD, Margara R, Winston RML, Seppäla M, Koistinen R, Franks S. Insulin-like growth factor-1 (IGF-I) inhibits production of IGF-binding protein-1 while stimulating estradiol secretion in granulosa cells from normal and polycystic human ovaries. J Clin Endocrinol Metab1993;76:1275-1279.
19.
19. Powell DR, Suwanichkul A, Cubbage ML, DePaolis LA, Snuggs MB, Lee PDK. Insulin inhibits transcriptin of the human gene for insulin-like growth factor binding protein-1. J Biol Chem1991;266:18868-18871.
21. Ezzat S, Ren SG, Braunstein GD, Melmed S. Octreotide stimulates insulin-like growth factor-binding protein-1: A potential pituitary independent mechanism for drug action. J Clin Endocrinol Metab1992;75:1459-1463.
22.
22. Horskov H. Wolthers T, Grofte T, Flyvbjerg A, Vilstrup H, Hamberg O. Somatostatin-stimulated insulin-like growth factor binding protein-1 release is abolished by hyperinsulinemia. J Clin Endocrinol Metab1994;78:138-140.
23.
23. Wolthers T, Grofte T, Flyrbjerg A, et al. Dose dependent stimulation of insulin-like growth factor binding protein-1 by Laureotide, a somatostatin analog. J Clin Endocrinol Metab1994;78:141-144.
24.
24. Rutanen EM, Karkkainen T, Stenman U-H, Yki-Jarvinen H. Aging is associated with decreased suppression of insulin-like growth factor binding protein-1 by insulin. J Clin Endocrinol Metab1993;77:1152-1155.
25.
25. Fredstorp L, Werner S, Bang P, Hall K. Inverse correlation between insulin-like growth factor binding protein-1 and insulin in patients with acromegaly during treatment with the somatostatin analogue octreotide. Clin Endocrinol1994;42:495-501.
26.
26. Cotterill AM, Holly JMP, Amiel S, Wass JAH. Suppression of endogenous insulin secretion regulates the rapid rise of insulin-like growth factor binding protein (JGFBP)-1 levels following acute hypoglycemia. Clin Endocrinol1993;38:633-639.
27.
27. Conover CA, Butler PC, Wang M. Rizza RA, Lee PDK. Lack of growth hormone effect on insulin-associated suppression of insulin-like growth factor binding protein 1 in humans. Diabetes1990;39:1251-1256.
28.
28. Conover CA, Lee PDK. Insulin regulation of IGF binding protein production in cultured HepG2 cells. J Clin Endocrinol Metab1990;70:1062-1067.
29.
29. Lee PDK, Jensen MD, Divertic D, Heiling VJ, Katz HH, Conover CA. Insulin-like growth factor-binding protein-1 response to insulin during suppression of endogenuous insulijn secretion. Metabolism1993;42:409-414.
30.
30. COnover CA, Lee PDK, Kanaley JA, Clarkson JT, Jensen MD. Insulin growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab1992;74:1355-1360.
32. Cox GN, McDermott MJ, Merkel E, et al. Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-1 and growth hormone in hypophysectomized rats. Endocrinology1994;135:1913-1920.
33.
33. Frystyk J, Skaerback C, Dinesen B, Orskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett1994;348:185-191.
